* Human Genome Sciences Inc., of Rockville, Md., received $25million as the final milestone payment from SmithKline Beechamplc, of London, in their $125 million collaboration. Of the $25million, about $18.1 million was an equity investment through thepurchase of 339,065 shares of Human Genome Sciences at $53.28per share. (See BioWorld Today, Jan. 16, 1996, p. 1.)
* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., said itcompleted dosing in the company's 270-patient Phase III trial of itslead drug, Allervax Cat, for treatment of people allergic to cats. Thestudy is expected to be complete by the end of March 1996 andresults should be available within the following three months.
* MedImmune Inc., of Gaithersburg, Md., boosted the funding fromits 3 million share follow-on offering to $62 million with the sale ofan additional 450,000 shares to the underwriters to coveroverallotments. Morgan Stanley & Co., of New York, and VectorSecurities International Inc., of Deerfield, Ill., managed the offering.Total net proceeds for MedImmune from the offering, priced at $18per share, were about $58.4 million. (See BioWorld Today, Feb. 15,p. 1.)
* Sequus Pharmaceuticals Inc., of Menlo Park, received EuropeanUnion approval of Doxil, a liposomal form of doxorubicin, as a first-and second-line therapy against AIDS related Kaposi's sarcoma. Thedrug was approved in the U.S. in December 1995 as a second-linetreatment for the same indication.
(c) 1997 American Health Consultants. All rights reserved.